Glaxo to make 1 billion doses of coronavirus vaccine booster

The adjuvant can reduce the amount of vaccine required per dose, allowing more people to be immunized, and create longer-lasting immunity, Glaxo says.

HIV drug patients’ privacy violated by Gilead, lawsuit claims

Gilead may have inadvertently revealed identities of thousands of people who are taking a medicine to prevent them from coming down with HIV.

HIV drug patients’ privacy violated by Gilead, lawsuit claims

Gilead may have inadvertently revealed identities of thousands of people who are taking a medicine to prevent them from coming down with HIV.

Gilead’s COVID-19 drug seen in short supply for Americans

The U.S. will get less than half of Gilead Sciences Inc.'s worldwide donation of 1.5 million vials of its COVID-19 medicine over the next six weeks, which isn't expected to be enough to treat all the patients who would qualify for it.

Gilead’s COVID-19 drug seen in short supply for Americans

The U.S. will get less than half of Gilead Sciences Inc.'s worldwide donation of 1.5 million vials of its COVID-19 medicine over the next six weeks, which isn't expected to be enough to treat all the patients who would qualify for it.

Pharmaceutical giant Pfizer begins testing coronavirus vaccine in people

Pfizer has begun testing an experimental coronavirus vaccine in healthy, young people in the United States, a first step toward establishing the safety, dosage and most promising candidate to take into larger trials that will test effectiveness.

Pharmaceutical giant Pfizer begins testing coronavirus vaccine in people

Pfizer has begun testing an experimental coronavirus vaccine in healthy, young people in the United States, a first step toward establishing the safety, dosage and most promising candidate to take into larger trials that will test effectiveness.
More Stories

Company says drug proved effective against virus in U.S. study

Gilead Sciences’ remdesivir would be the first treatment to pass such a test against the virus, which has killed more than 218,000 people since it emerged late last year.

Column

Payback beyond borders: Philly profs, pharma pros aided China as virus hit. Now PPE arrives, in thanks

Doctors here tapped friends in China to collect more than 70,000 medical, surgical, N95, and KN95 masks, 45,000 exam gloves, plus sanitizer, coveralls, and goggles worth more than $250,000.

GSK joins Sanofi effort to make coronavirus vaccine

The two pharma giants plan to start testing the vaccine in humans during the second half of the year.

Hydroxychloroquine is not proven to work against the coronavirus. Why not just try it?

'What do you have to lose?' President Trump asked. Maybe nothing, but without a formal study, we'll never know.

Experimental coronavirus vaccine given to Philadelphia volunteers

The first dose of the vaccine, made by Inovio Pharmaceuticals of Plymouth Meeting, was given to volunteers Monday at the University of Pennsylvania.

DEA relaxes rules for the only federally approved drug derived from marijuana

On Monday, the DEA notified GW Pharma that it no longer considered Epidiolex a controlled substance under the federal Controlled Substance Act.

Column

Coronavirus has created a new golden age for vaccines, and Philly is at the heart of it

Merck and GlaxoSmithKline labs in the western suburbs and start-ups in University City have been at the forefront of developing new generations of vaccines.

Why a coronavirus vaccine may take 18 months to be ready

Vaccines for the coronavirus are being made faster than any vaccines before. But testing them for safety still requires time and care.

Coronavirus-curing toothpaste? $100 for toilet paper? Anxiety over spread of disease ignites a rush of virus-related scams

Toothpaste that prevents the virus' spread? Emails demanding payment to treat sick relatives? Too-good-to-be-true offers to work from home for Amazon? National anxiety over the coronavirus has triggered a rush of scammers, snake-oil purveyors, and hucksters.

Why the coronavirus and most other viruses have no cure

We’ve had effective antibiotics for close to a century, but relatively few antiviral drugs. The reasons involve biology and money.

Column

PhillyDeals: Why city can’t rest on its rep as a ‘Cradle of Cures’; Judge moves RICO case against a school pension manager towards trial

Another promising, well-funded -- and already Philly-based -- biotech developer, Century Therapeutics, announced that it, too, is opening its own R&D lab in a biotech hotspot -- all the way across the country, in Seattle.

Teamsters lost a shareholder vote on executive bonuses at AmerisourceBergen. They still view the results as ‘remarkable.'

"This was a huge wake-up call” for the Chesterbrook-based AmerisourceBergen, said Michael Pryce-Jones, a senior governance analyst with the Teamsters.

Amicus opens UCity R&D tower, calls Philly the ‘Cradle of Cures’

A Princeton-area biotech company has moved its R&D to Philadelphia, where it will employ 200, because, its founder says, this is where the genetic scientists are. Plus, Boston is full

SPECIAL REPORTS
Investigative reports, featured series, and guides to living in the Philadelphia region, brought to you by The Inquirer.
WHAT ARE YOU CURIOUS ABOUT?
Send us your burning questions, or vote on other readers' questions that pique your interest. Our journalists will work to answer them.